Published

Semaglutide

A GLP-1 receptor agonist and FDA-approved medicine (Ozempic, Wegovy, Rybelsus) with an extensive clinical literature; in the peptide world the live issue is compounding, not approval.

Primary sources

Clinical

Evidence stage

Jul 2026

Last reviewed

What it is

Semaglutide is a GLP-1 receptor agonist, marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management).S1

Marketed as

As approved products, semaglutide is marketed for type 2 diabetes and weight management; it is also widely promoted off-label and through compounders / telehealth purely for weight loss. The approved uses are evidence-backed (below); the compounded / off-label weight-loss promotion is a separate marketing landscape.S1

Regulatory status (US)

Unlike the other catalog peptides, semaglutide is an FDA-approved drug. The live regulatory question is not approval but compounding: FDA has proposed to exclude semaglutide (with tirzepatide and liraglutide) from the 503B bulks list, finding no clinical need to compound them from bulk. The public comment period closed June 29, 2026, and a final determination is pending.S1 See compounded-semaglutide-enforcement for the full timeline.

Around the world

Unlike the others here, semaglutide is an approved medicine well beyond the US — cleared by the EU's EMA, the UK's MHRA, and dozens of other markets, and sold as Ozempic, Wegovy, and Rybelsus.S1 The cross-border wrinkle isn't the drug itself but compounded copies, a largely US-specific regulatory fight.S1

Evidence

Semaglutide has a robust randomized-trial base for glycemic control, weight reduction, and cardiovascular risk in its approved indications. Efficacy statements should stay tied to the approved labeling and cited trials — not to compounded or off-label formulations.

Anti-doping

Semaglutide is not prohibited in sport. From January 1, 2026, WADA placed markers of semaglutide (and tirzepatide) on its Monitoring Program, tracked in- and out-of-competition to watch for misuse. Monitoring is surveillance, not a ban.S2 S3

⚑ Provisional

WADA is reported to be considering whether to add GLP-1 agonists to the Prohibited List ahead of LA 2028, with a decision expected late 2026 / 2027. Treat this as a possible future change, not current status. S3

Safety

As an approved drug, semaglutide's safety is governed by its FDA labeling. Separately, FDA and FTC have warned about unapproved or compounded GLP-1 products marketed for weight loss — a distinct safety issue from the approved product.S1

What's changing

Two things to watch: FDA's final determination on the 503B bulks-list exclusion, and the WADA question in the Anti-doping caveat above.S1 S3

Sources

Every reference below is a primary source cited in this entry, drawn from the approved corpus.

01
FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
fda.gov · Federal regulatory statement
02
NADA Germany — WADA publishes Prohibited List 2026 (Monitoring Program)
nada.de · National anti-doping organization
03
Triathlon Magazine — 2026 WADA Prohibited List and the status of semaglutide
triathlonmagazine.ca · Sports media

Follow this compound

Get an email when FDA / WADA / ClinicalTrials moves on Semaglutide.

Follow this

The Panel Brief

What moved in supplement & peptide regulation this week. Free, cited, unsubscribe anytime.